Welcome to our dedicated page for Ardelyx SEC filings (Ticker: ARDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Ardelyx, Inc. (Nasdaq: ARDX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a biopharmaceutical issuer with commercial products IBSRELA and XPHOZAH and an active development pipeline, Ardelyx uses SEC reports to describe its financial condition, risk factors, governance and material corporate events.
Current reports on Form 8-K referenced in recent disclosures cover topics such as quarterly financial results, amendments to loan and security agreements, changes to equity incentive plans and bylaws, and transitions in senior management roles. For example, Ardelyx has filed 8-Ks describing appointments and resignations of executive officers, the approval of amendments to its 2014 Equity Incentive Award Plan at the annual meeting of stockholders, and changes to its loan facilities, including new term loans and updated maturity dates.
On this page, users can also locate periodic reports such as Forms 10-K and 10-Q, which contain detailed financial statements, management’s discussion and analysis, descriptions of the company’s products IBSRELA and XPHOZAH, discussions of its NHE3 inhibitor pipeline and summaries of key risks related to drug development and commercialization. These filings provide context for revenue from tenapanor-based products, licensing arrangements with partners such as Kyowa Kirin, Fosun Pharma and Knight Therapeutics, and capital structure information.
Stock Titan enhances access to Ardelyx filings with AI-powered summaries that highlight important sections in lengthy documents, such as annual reports on Form 10-K and quarterly reports on Form 10-Q. Users can also review filings related to executive compensation, equity plans and governance changes, as disclosed in proxy materials and associated 8-Ks. Real-time updates from the EDGAR system help ensure that new Ardelyx filings, including future 8-Ks reporting material events, are reflected promptly for investors and researchers.
ARDELYX, INC. Chief Medical Officer Dinavahi Rajani reported her equity holdings in connection with a Form 3 filing. She holds stock options to purchase 301,000 shares of Common Stock at an exercise price of $6.11 per share, expiring on April 1, 2036.
She also directly holds 201,000 shares of Common Stock. The option grant vests over time, with 25% of the shares vesting on April 1, 2027 and the remainder vesting in 36 equal monthly installments thereafter, subject to her continued employment or service with the company.
Ardelyx Inc received an amended Schedule 13G/A from The Vanguard Group reporting that, following an internal realignment, Vanguard and its subsidiaries/ divisions will report holdings separately. The filing states amount beneficially owned: 0 and percent of class: 0% as of 03/13/2026.
The amendment cites SEC Release No. 34-39538 (January 12, 1998) and explains that certain Vanguard subsidiaries that formerly were reported under The Vanguard Group, Inc. will now report on a disaggregated basis. The signing official is Ashley Grim, Head of Global Fund Administration, dated 03/26/2026.
ARDELYX, INC. President & CEO Michael Raab exercised stock options to acquire 20,833 shares of common stock at $0.99 per share, then sold 41,666 shares at a weighted average price of $5.84 per share under a pre-arranged Rule 10b5-1 trading plan.
After these transactions, he held 1,816,448 common shares directly and 374,168 stock options of this award, plus indirect holdings of 24,364 and 1,000 shares through family trusts for his children.
ARDELYX, INC. President & CEO Michael Raab reported option exercises and share sales in ARDX. He exercised stock options for 20,833 shares of common stock at an exercise price of $0.99 per share through a derivative conversion. The resulting 20,833 common shares were acquired and then partially offset by an open-market sale of 41,666 common shares at a weighted average price of $6.255 per share, executed in multiple trades between $6.08 and $6.56. The sale was made under a Rule 10b5-1 trading plan adopted on November 7, 2025. After these transactions, Raab directly held 1,836,153 common shares, with additional shares held indirectly through family trusts for his children.
Morgan Stanley Smith Barney LLC submitted a Form 144 reporting proposed sales of common stock tied to exercises and restricted stock units. The notice lists proposed sales of 83,333 shares on 02/24/2026 (exercise of stock options) and 83,333 shares from restricted stock units with a grant date of 02/19/2024. The filing also discloses a sale by Michael G. Raab of 45,982 shares on 02/20/2026 for $268,840.52.
Ardelyx director David M. Mott reported an open-market purchase of 333,333 shares of Ardelyx common stock. The weighted average purchase price was $5.839 per share, with individual trades executed between $5.67 and $6.00 per share. Following this transaction, he reports ownership of 3,302,918 shares, which includes 87,566 shares he holds for the benefit of entities associated with New Enterprise Associates, for which he disclaims beneficial ownership except to the extent of his pecuniary interest.
ARDELYX, INC. officer John E. Bishop reported automatic sales of company common stock tied to the vesting of restricted stock units. On February 20, 2026, a total of 3,179 shares of common stock were sold in several open-market transactions at prices between $5.70 and $5.87 per share. According to the footnote, these were automatic “sell-to-cover” transactions executed solely to cover withholding taxes due upon RSU vesting, rather than discretionary sales. After these tax-related sales, Bishop directly held 339,151 shares of Ardelyx common stock.
ARDELYX, INC. executive Joseph James Reilly reported open-market sales of 4,991 shares of common stock on February 20, 2026, at prices between $5.7003 and $5.865 per share. According to the footnote, these transactions were automatic sell-to-cover trades upon RSU vesting, executed solely to cover withholding taxes. After the sales, Reilly directly owned 151,790 Ardelyx shares.
ARDELYX, INC. executive Laura A. Williams reported automatic sales of company common stock tied to restricted stock unit (RSU) vesting. On February 20, 2026, she sold 7,192 shares at $5.865 and 984 shares at $5.7138 in open-market transactions. A footnote explains these were “sell-to-cover” transactions required by the RSU grant terms to cover withholding taxes upon vesting, rather than discretionary sales. Following these sales, she continued to hold over four hundred thousand Ardelyx shares directly.
ARDELYX, INC. Chief Financial Officer Susan Hohenleitner reported an automatic tax-related sale of company stock. On February 20, 2026, she sold a total of 2,033 shares of common stock in open-market transactions, at prices of $5.865 and $5.7138 per share. According to a footnote, these sales were an automatic sell-to-cover triggered by vesting restricted stock units and were made solely to cover withholding taxes. After these transactions, she directly owned 230,533 shares of Ardelyx common stock.